Bofanglutide
GZR18-BWM-303
Gan & Lee Pharmaceuticals · Phase 3 · Recruiting · Enrollment 500
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| GZR18 injection Dose1 | n/r | n/r | n/r | n/r |
| GZR18 injection Dose2 | n/r | n/r | n/r | n/r |
| GZR18 injection Dose3 | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- GZR18 injection Dose1: endpoint not reported
- GZR18 injection Dose2: endpoint not reported
- GZR18 injection Dose3: endpoint not reported